GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 2,089,377 shares, a decline of 20.5% from the February 12th total of 2,629,402 shares. Currently, 20.3% of the shares of the stock are sold short. Based on an average trading volume of 923,696 shares, the days-to-cover ratio is currently 2.3 days. Based on an average trading volume of 923,696 shares, the days-to-cover ratio is currently 2.3 days. Currently, 20.3% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in GT Biopharma stock. Bank of Montreal Can increased its stake in shares of GT Biopharma, Inc. (NASDAQ:GTBP) by 531.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,530 shares of the company’s stock after buying an additional 77,879 shares during the period. Bank of Montreal Can owned 2.83% of GT Biopharma worth $331,000 at the end of the most recent quarter. 8.15% of the stock is currently owned by institutional investors and hedge funds.

GT Biopharma Stock Up 2.5%

GTBP stock traded up $0.01 during midday trading on Monday, reaching $0.42. 526,927 shares of the company’s stock traded hands, compared to its average volume of 817,828. The company has a 50-day simple moving average of $0.56 and a two-hundred day simple moving average of $0.68. GT Biopharma has a 1-year low of $0.39 and a 1-year high of $3.85. The company has a market cap of $4.52 million, a price-to-earnings ratio of -0.06 and a beta of 1.29.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of GT Biopharma in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).